AtriCure to Participate in the UBS Global Healthcare Conference
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. A live audio webcast of the presentation will be accessible through the Investors section of AtriCure's website.
AtriCure (Nasdaq: ATRC), un'azienda specializzata nei trattamenti chirurgici per fibrillazione atriale, gestione dell'appendice atriale sinistra e gestione del dolore post-operatorio, ha annunciato la sua partecipazione alla prossima UBS Global Healthcare Conference. La direzione dell'azienda parteciperà a un incontro informale il martedì 12 novembre 2024, alle 17:00 ora del Pacifico. Un webcast audio in diretta della presentazione sarà accessibile attraverso la sezione Investitori del sito web di AtriCure.
AtriCure (Nasdaq: ATRC), una empresa especializada en tratamientos quirúrgicos para fibrilación auricular, manejo de la orejuela auricular izquierda y manejo del dolor postoperatorio, ha anunciado su participación en la próxima Conferencia Global de Salud de UBS. La dirección de la empresa participará en una charla informal el martes 12 de noviembre de 2024, a las 5:00 pm, hora estándar del Pacífico. Una transmisión de audio en vivo de la presentación estará disponible a través de la sección de Inversores del sitio web de AtriCure.
AtriCure (Nasdaq: ATRC)은 심방세동, 좌심방 부속기 관리 및 수술 후 통증 관리에 대한 외과 치료를 전문으로 하는 회사로, 다가오는 UBS 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 11월 12일 화요일 오후 5:00 태평양 표준시(PT)에 화상 대화에 참여할 예정입니다. 발표의 생중계 오디오 웹캐스트는 AtriCure 웹사이트의 투자자 섹션을 통해 접속할 수 있습니다.
AtriCure (Nasdaq: ATRC), une entreprise spécialisée dans les traitements chirurgicaux pour fibrillation auriculaire, gestion de l'appendice auriculaire gauche et gestion de la douleur post-opératoire, a annoncé sa participation à la prochaine Conférence Mondiale sur les Soins de Santé de UBS. La direction de l'entreprise participera à une discussion informelle le mardi 12 novembre 2024, à 17h00, heure normale du Pacifique. Un webcast audio en direct de la présentation sera accessible via la section Investisseurs du site Web d'AtriCure.
AtriCure (Nasdaq: ATRC), ein Unternehmen, das sich auf chirurgische Behandlungen von Vorhof-Flimmern, der Verwaltung des linken Vorhofohres und der Schmerzbehandlung nach der Operation spezialisiert hat, hat seine Teilnahme an der bevorstehenden UBS Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Dienstag, den 12. November 2024, um 17:00 Uhr pazifische Zeit an einem informellen Gespräch teilnehmen. Ein Live-Audio-Webcast der Präsentation wird über den Bereich Investoren auf der Website von AtriCure zugänglich sein.
- None.
- None.
AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028461412/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
marissa@gilmartinir.com
Source: AtriCure, Inc.
FAQ
When is AtriCure (ATRC) presenting at the UBS Global Healthcare Conference 2024?
How can investors watch AtriCure's (ATRC) UBS Conference presentation?
What type of presentation will AtriCure (ATRC) give at the UBS Healthcare Conference?
What medical conditions does AtriCure (ATRC) focus on treating?
